Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (101)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas

    International Journal of Gynecological Cancer, Vol. 34, Núm. 10, pp. 1499-1521

  3. Sotorasib in KRASG12C mutated lung cancer – Authors' reply

    The Lancet

  4. Sotorasib versus docetaxel: evidence supporting CodeBreaK 200

    The Lancet Oncology

  5. Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update

    Journal of Clinical Oncology, Vol. 42, Núm. 29, pp. 3392-3399

2023

  1. A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2

    Human Mutation, Vol. 2023

  2. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

    Cancer Medicine, Vol. 12, Núm. 15, pp. 16142-16162

  3. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

    Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1849-1863

  4. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86

  5. Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis

    Oncologist, Vol. 28, Núm. 6, pp. E406-E415

  6. European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors

    International Journal of Gynecological Cancer, Vol. 33, Núm. 10, pp. 1621-1626

  7. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

    Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197

  8. Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

    Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212

  9. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194

  10. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

    Cancer Medicine, Vol. 12, Núm. 11, pp. 12071-12083

  11. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

  12. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

  13. Stoma-free survival after anastomotic leak following rectal cancer resection: worldwide cohort of 2470 patients

    British Journal of Surgery, Vol. 110, Núm. 12, pp. 1863-1876

  14. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2893-2903

  15. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

    Cell Reports Medicine, Vol. 4, Núm. 11